Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Check Note
Ver. Summary Created by Modification Content Size Created at Operation
1 + 535 word(s) 535 2020-12-15 07:14:23

ACAD9 deficiency is a condition that varies in severity and can cause muscle weakness (myopathy), heart problems, and intellectual disability. Nearly all affected individuals have a buildup of a chemical called lactic acid in the body (lactic acidosis). Additional signs and symptoms that affect other body systems occur in rare cases.

genetic conditions
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 175
Entry Collection: MedlinePlus
Revision: 1 time (View History)
Update Date: 23 Dec 2020
Table of Contents

    1. Introduction

    Mildly affected individuals with ACAD9 deficiency usually experience nausea and extreme fatigue in response to physical activity (exercise intolerance). People with ACAD9 deficiency who are moderately affected have low muscle tone (hypotonia) and weakness in the muscles used for movement (skeletal muscles). Severely affected individuals have brain dysfunction combined with myopathy (encephalomyopathy); these individuals usually also have an enlarged and weakened heart muscle (hypertrophic cardiomyopathy), which is typically fatal in infancy or childhood.

    Individuals with ACAD9 deficiency who survive past early childhood often have intellectual disability and may develop seizures. Rare signs and symptoms of ACAD9 deficiency include movement disorders and problems with liver and kidney function.

    Some individuals with ACAD9 deficiency have had improvement in muscle strength and a reduction in lactic acid levels with treatment.

    2. Frequency

    The prevalence of ACAD9 deficiency is unknown. At least 25 people with this condition have been described in the scientific literature.

    3. Causes

    ACAD9 deficiency is caused by mutations in the ACAD9 gene. This gene provides instructions for making an enzyme that is critical in helping assemble a group of proteins known as complex I. Complex I is found in mitochondria, which are the energy-producing structures inside cells. Complex I is one of several complexes that carry out a multistep process called oxidative phosphorylation, through which cells derive much of their energy.

    The ACAD9 enzyme also plays a role in fatty acid oxidation, a multistep process that occurs within mitochondria to break down (metabolize) fats and convert them into energy. The ACAD9 enzyme helps metabolize a certain group of fats called long-chain fatty acids. Fatty acids are a major source of energy for the heart and muscles. During periods without food (fasting), fatty acids are also an important energy source for the liver and other tissues.

    Some ACAD9 gene mutations disrupt complex I assembly as well as long-chain fatty acid oxidation, while others affect only complex I assembly. The mutations that affect both of the enzyme's functions tend to be associated with the most severe signs and symptoms of ACAD9 deficiency, such as encephalomyopathy and hypertrophic cardiomyopathy. Although the exact mechanism is unclear, it is likely that cells that are less able to produce energy die off, particularly cells in the brain, skeletal muscle, and other tissues and organs that require a lot of energy. The loss of cells in these tissues is thought to lead to the signs and symptoms of ACAD9 deficiency.

    4. Inheritance

    This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

    5. Other Names for This Condition

    • acyl-CoA dehydrogenase 9 deficiency

    • deficiency of acyl-CoA dehydrogenase family member 9

    • mitochondrial complex I deficiency due to ACAD9 deficiency


    1. Aintablian HK, Narayanan V, Belnap N, Ramsey K, Grebe TA. An atypicalpresentation of ACAD9 deficiency: Diagnosis by whole exome sequencing broadensthe phenotypic spectrum and alters treatment approach. Mol Genet Metab Rep. 2016 Dec 29;10:38-44. doi: 10.1016/j.ymgmr.2016.12.005.
    2. Collet M, Assouline Z, Bonnet D, Rio M, Iserin F, Sidi D, Goldenberg A,Lardennois C, Metodiev MD, Haberberger B, Haack T, Munnich A, Prokisch H, RötigA. High incidence and variable clinical outcome of cardiac hypertrophy due toACAD9 mutations in childhood. Eur J Hum Genet. 2016 Aug;24(8):1112-6. doi:10.1038/ejhg.2015.264.
    3. Dewulf JP, Barrea C, Vincent MF, De Laet C, Van Coster R, Seneca S, Marie S,Nassogne MC. Evidence of a wide spectrum of cardiac involvement due to ACAD9mutations: Report on nine patients. Mol Genet Metab. 2016 Jul;118(3):185-9. doi: 10.1016/j.ymgme.2016.05.005.
    4. Gerards M, van den Bosch BJ, Danhauser K, Serre V, van Weeghel M, Wanders RJ, Nicolaes GA, Sluiter W, Schoonderwoerd K, Scholte HR, Prokisch H, Rötig A, de CooIF, Smeets HJ. Riboflavin-responsive oxidative phosphorylation complex Ideficiency caused by defective ACAD9: new function for an old gene. Brain. 2011Jan;134(Pt 1):210-9. doi: 10.1093/brain/awq273.
    5. Haack TB, Danhauser K, Haberberger B, Hoser J, Strecker V, Boehm D, Uziel G,Lamantea E, Invernizzi F, Poulton J, Rolinski B, Iuso A, Biskup S, Schmidt T,Mewes HW, Wittig I, Meitinger T, Zeviani M, Prokisch H. Exome sequencingidentifies ACAD9 mutations as a cause of complex I deficiency. Nat Genet. 2010Dec;42(12):1131-4. doi: 10.1038/ng.706.
    6. Nouws J, Nijtmans L, Houten SM, van den Brand M, Huynen M, Venselaar H, Hoefs S, Gloerich J, Kronick J, Hutchin T, Willems P, Rodenburg R, Wanders R, van denHeuvel L, Smeitink J, Vogel RO. Acyl-CoA dehydrogenase 9 is required for thebiogenesis of oxidative phosphorylation complex I. Cell Metab. 2010 Sep8;12(3):283-94. doi: 10.1016/j.cmet.2010.08.002.
    7. Nouws J, Te Brinke H, Nijtmans LG, Houten SM. ACAD9, a complex I assemblyfactor with a moonlighting function in fatty acid oxidation deficiencies. Hum MolGenet. 2014 Mar 1;23(5):1311-9. doi: 10.1093/hmg/ddt521.
    8. Schiff M, Haberberger B, Xia C, Mohsen AW, Goetzman ES, Wang Y, Uppala R,Zhang Y, Karunanidhi A, Prabhu D, Alharbi H, Prochownik EV, Haack T, Häberle J,Munnich A, Rötig A, Taylor RW, Nicholls RD, Kim JJ, Prokisch H, Vockley J.Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9both contribute to disease severity in ACAD9 deficiency. Hum Mol Genet. 2015 Jun 1;24(11):3238-47. doi: 10.1093/hmg/ddv074.
    9. Schrank B, Schoser B, Klopstock T, Schneiderat P, Horvath R, Abicht A,Holinski-Feder E, Augustis S. Lifetime exercise intolerance with lactic acidosis as key manifestation of novel compound heterozygous ACAD9 mutations causingcomplex I deficiency. Neuromuscul Disord. 2017 May;27(5):473-476. doi:10.1016/j.nmd.2017.02.005.
    Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
    View Times: 175
    Entry Collection: MedlinePlus
    Revision: 1 time (View History)
    Update Date: 23 Dec 2020
    Table of Contents


      Are you sure to Delete?

      Video Upload Options

      Do you have a full video?
      If you have any further questions, please contact Encyclopedia Editorial Office.
      Yang, C. ACAD9 Deficiency. Encyclopedia. Available online: (accessed on 02 June 2023).
      Yang C. ACAD9 Deficiency. Encyclopedia. Available at: Accessed June 02, 2023.
      Yang, Catherine. "ACAD9 Deficiency" Encyclopedia, (accessed June 02, 2023).
      Yang, C. (2020, December 23). ACAD9 Deficiency. In Encyclopedia.
      Yang, Catherine. "ACAD9 Deficiency." Encyclopedia. Web. 23 December, 2020.